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Cord colitis syndrome after umbilical cord blood transplantation (UCBT) involves late-onset diarrhea, absence
of infection or GVHD, chronic active colitis, and granulomatous inﬂammation that responds to antibiotics. We
tested the hypothesis that Seattle recipients of UCBT had late-occurring colitis distinct from GVHD and colitis
in other allograft recipients. We conducted a blinded histological review of 153 colon biopsy specimens from
45 UCBT recipients and 45 matched allografted controls obtained between day þ70 and day þ365 post-
transplantation. Diarrhea was the primary indication for biopsy in 10 UCBT recipients and 11 controls. No
histological differences were seen between UCBT recipients and controls with diarrhea or between the entire
cohort of UCBT recipients and their controls. Distorted mucosal architecture and apoptotic crypt cells typical
of GVHD were common in both groups; Paneth cell metaplasia and granulomas were rare ﬁndings. Chronic
active colitis was present in 58% of the UCBT recipients and in 62% of controls. No UCBT recipient with
diarrhea was treated with antibiotics, and all recipients responded to systemic corticosteroids. Colitis
occurring after day þ70 in allografted controls was related to acute GVHD, independent of the source of donor
cells. We could not identify a histologically distinct cord colitis syndrome in either the UCBT or the nonecord
blood allograft recipients.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION metronidazole alone or in combination with a ﬂuo-
An advantage of using umbilical cord blood (CB) as the
cell source for allogeneic hematopoietic cell transplantation
is the tolerance of signiﬁcant HLA disparity between donor
and recipient, thus allowing identiﬁcation of donors for
nearly all patients. Despite the marked degree of HLA
mismatch between CB donors and recipients, acute and
chronic graft-versus-host disease (GVHD) do not appear to
occur with higher frequency after umbilical cord blood
transplantation (UCBT) compared with other, better-
matched hematopoietic cell sources [1-5]. However, recent
studies have identiﬁed the gastrointestinal tract as the most
commonly involved anatomic site of acute, late acute, and
chronic GVHD after single and double UCBT [6,7]. In one of
these studies, most of these cases responded to either local or
systemic immunosuppressive therapy [6].
In 2011, Herrera et al. [8] described a new entity that they
termed “cord colitis syndrome” (CCS), affecting 11% of pa-
tients undergoing UCBT and with clinical and histopatho-
logical features distinct from gastrointestinal GVHD.
Clinically, those patients labeledwith CCS presentedwith the
onset of watery diarrhea between day þ88 and day þ365
post-transplantation and responded to therapy withedgments on page 1013.
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histological changes seen in GVHD of the colon in having
relatively mild or no apoptotic changes with architectural
distortion of the crypts [8]. The histological criteria for GVHD
of Herrera et al. differ from those speciﬁed in the National
Institutes of Health’s histopathology consensus document
[9]. The histological features of CCS are those of chronic
active colitis, along with the presence of epithelioid granu-
lomas, basal cell plasmacytosis, and Paneth cell metaplasia.
In the study reported here, we reviewed clinical and
histological features of all patients who underwent UCBT in
Seattle over a 5-year period and who had colon tissue
available from biopsy specimens obtained between day þ70
and day þ365 after transplantation. Our patient selection
criteriawere intended tomimic the published criteria for and
clinical description of cord colitis while avoiding selection
biases. We also reviewed a matched control patient group
consisting of patients who received an allograft using bone
marrow (BM) or peripheral blood (PB) hematopoietic cells
and who had colon tissue biopsy specimens obtained in the
same time interval post-transplantation. Anymucosal biopsy
specimens taken from the stomach and duodenum at the
same time as the colon specimens were reviewed as well. All
coded tissue sections were reviewed without knowledge of
the hematopoietic cell source. The hypothesis testedwas that
recipients of UCBT have late-occurring colitis that is distinct
from that seen in recipients of BM or PB allografts, thus
representing a unique clinical entity.Transplantation.
Figure 1. Formation of the study sample.
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Patients
All patients (n ¼ 135) who underwent UCBT at the Fred Hutchinson
Cancer Research Center between January 2006 and March 2011 were
eligible for inclusion in this study (Figure 1). UCBT recipients with colon
biopsy specimens obtained between day þ70 and day þ365 post-
transplantation were included in the analysis. Patients were eligible for
the control group if they had undergone hematopoietic cell transplantation
using either BM or PB cell sources, and had at least 1 colon biopsy specimen
obtained between day þ70 and day þ365 after transplantation. Of the 287
eligible control patients, 1 was selected at random for each case with
matching on year of transplantation and post-transplantation day of the ﬁrst
colon biopsy.
Protocols encompassing the review of both clinical and histological
materials were approved by the Fred Hutchinson Cancer Research Center’s
Institutional Review Board.Transplantation Practices
Patients received a double UBCT (dUCBT) if a suitable single CB graft
could not be found, based on institutional criteria. Selected CB units were
required to be matched to the recipient at 4 of the 6 HLA loci based on
intermediate-resolution typing for HLA-A and -B and allele-level typing
for HLA-DRB1. Decisions regarding the use of high-intensity or reduced-
intensity conditioning regimens were made by the primary trans-
plantation teams.
All patients received prophylactic immunosuppressive therapy for pre-
vention of GVHD consisting of cyclosporine (or tacrolimus in 3 of 45 pa-
tients) and mycophenolate mofetil (MMF) for patients undergoing UCBT,
with a combination of methotrexate and tacrolimus the most common
therapy in the control group (Table 1). Severity of acute GVHD was graded
using standard clinical criteria based on organ involvement [10]. All patients
received prophylactic antimicrobial, antiviral, and antifungal agents during
follow-up [11]. Fecal specimens obtained within 7 days of the colon biopsy
date were analyzed. Microbiological evaluation included Clostridium difﬁcile
toxin assays, bacterial, viral, and fungal cultures and microscopy for ova and
parasites. Real-time PCR was used to evaluate the serum for evidence of
viremia with cytomegalovirus, adenovirus, BK virus, and Epstein-Barr virus
within 7 days of the colon biopsy date. Immunosuppressive, antiviral,
antibacterial, antifungal, and antiparasitic medications at the time of colon
biopsy were reviewed in all patients included in the analysis.Blinded Histopathological Review of Mucosal Biopsy Tissue
Endoscopic biopsy specimens from the study cohort and controls
included colonic and any concurrent specimens from the stomach duo-
denum or ileum. Archival histological material was reviewed by H.M.S., who
was blinded to all clinical information. Our biopsy practice involved col-
lecting a minimum of 4 specimens for histology from each anatomic area,
orienting and then ﬁxing the tissue in neutral buffered formalin, followed by
embedding and sectioning at 4 m. Specimens of colonic mucosa from each
locationwere placed into a single parafﬁn block, fromwhich 8 serial sections
were placed on a slide and stained with hematoxylin and eosin. Thus, for
each patient, a minimum of 32 serial sections of colonic tissue were
examined. In the majority of patients (cases and controls), more than 1
anatomic area of the colonwas biopsied, leading to an even larger number of
slides containing serial sections that were analyzed.Histological Scoring
Histological evaluation of colon biopsy specimens included assessment
of the presence or absence of granulomas, crypt architectural distortion,
Paneth cell metaplasia, and increasedmucosal eosinophils, plasma cells, and
neutrophils. When possible, an overall histological pattern was assessed
using endoscopic biopsy histology terminology [12], that is, chronic inactive
colitis, chronic active colitis (chronic changes with acute or mixed inﬂam-
matory cryptitis), active colitis, or normal [13]. Biopsy specimens were
considered unclassiﬁed if they did not ﬁt into any of the aforementioned
patterns or were normal. The histological criteria for GVHD in the colon and
upper gut specimens were based on National Institutes of Health consensus
criteria [9]. Our histological criteria for GVHD are based on an apoptotic
threshold, that is, the number of apoptoses in each tissue block, where
neither grade 0 (no apoptosis) or grade 1 (a single apoptotic body) is
considered diagnostic of GVHD. Both colon and upper endoscopy biopsy
specimens with at least 2 apoptoses (grade 2) are considered to establish our
minimal histological criteria for GVHD. Specimens with more than 2
apoptotic crypt cells are considered grade 3.We did not attempt to grade the
extent of mucosal damage, because this cannot be reliably determined by
histology of endoscopic biopsy specimens owing to signiﬁcant sampling
error.Statistical Analysis
Differences in patient characteristics between cases and controls were
evaluated using Wilcoxon rank-sum and chi-square tests. The prevalence of
the histological ﬁndings was summarized over multiple biopsy samples for
each patient, with overall apoptosis rate and lower gut acute GVHD grade
deﬁned as the most severe documented in the records. The statistical sig-
niﬁcance of differences in the prevalence of characteristics was evaluated
using the chi-square test or Fisher’s exact test. No adjustments were made
for multiple comparisons; however, given 20 outcome comparisons (10
outcomes analyzed in the complete cohort and in subgroups), we would
expect to see a signiﬁcant difference by chance at the P ¼ .05 level. Analyses
were performed using SAS version 9.3 (SAS Institute, Cary, NC).RESULTS
Patient Characteristics
Of 135 patients who underwent UCBT, 46 (34%) had colon
biopsy specimens obtained between day þ70 and day þ365
after transplantation. One of the 46 UCBT recipients had not
consented to the use of clinical data for the study, and colon
biopsy specimens from 2 patients were not evaluable. In the
control group, 3 patients did not have evaluable biopsy
specimens. Patient, transplantation, and graft characteristics
are summarized in Table 1 by case-control status. The 2
groups were similar in terms of age, intensity of conditioning
regimen, sex, and diagnosis. Thirty-nine patients (86%) in
each group were diagnosed with grade II-IV aGVHD; of these
patients, 26 (67%) in the UCBT group and 12 (31%) in the
control group had gastrointestinal tract involvement
(P ¼ .003). The incidence of grade II-IV aGVHD was signiﬁ-
cantly greater in UCBT recipients than in non-CB allograft
recipients: 23 of 45 (51%) versus 12 of 45 (27%) with peak
grade III-IV aGVHD (P ¼ .01). The timing of GVHD onset was
similar in the 2 groups: median, day þ22 (range, day þ9 to
day þ82) versus dayþ25 (range, dayþ10 to dayþ56). At the
time of the ﬁrst biopsy, UCBT recipients were more likely
than control patients to be receiving a combination of
cyclosporine and MMF, whereas patients in the control
group were more likely to be receiving a regimen containing
tacrolimus (Table 2). Only 3 patients (6%) in the UCBT group
and 5 patients (11%) in the control group were receiving
metronidazole before the biopsy procedure. Similarly, 3
patients (6%) in the UCBT group and 4 patients (8%) in the
control groupwere on ﬂuoroquinolone therapy at the time of
the ﬁrst biopsy. There were no differences in the use of
glucocorticoids, antibacterials, and antifungals between the
2 cohorts. In accordance with our institutional guidelines,
patients receiving UCBT were more likely than the control
group to be receiving valacyclovir (P ¼ .003).
Table 1
Patient Characteristics
Characteristic UCBT
(n ¼ 45)
Control
(n ¼ 45)
P Value
Age, yr, median (IQR) 18 (0.6-68) 33 (0.7-64) .15
Sex, n (%)
Female 29 (65) 23 (51) .20
Male 16 (35) 22 (49) .20
Race, n (%)
Caucasian 19 (42) 26 (58) .14
Other 26 (58) 19 (42) .14
Disease, n (%)
AML 16 (36) 11 (24) .76
ALL 15 (33) 19 (42) .76
MDS 4 (9) 4 (9) .76
Other 10 (22) 11 (24) .76
Transplant type, n (%)
Myeloablative 37 (82) 37 (82) 1.00
Nonmyeloablative 9 (18) 9 (18) 1.00
GVHD prophylaxis, n (%)
Cyclosporine þ MMF 42 (93) 3 (7)
Tacrolimus þ MMF 3 (7) —
Cyclophosphamide þ tacrolimus — 7 (15)
Tacrolimus þ MTX — 34 (76)
Other — 1 (2)
Acute GVHD, n (%)
Grade 0-II 22 (49) 33 (73) .01
Grade III-IV 23 (51) 12 (27) .01
Stem cell source, n (%)
CB 45 — —
PB — 20 (44) —
BM — 25 (56) —
Type of transplant
Single CB 7 (15) — —
Double CB 38 (85) — —
Matched related — 10 (22) —
Matched unrelated — 25 (56) —
Mismatched unrelated — 2 (4) —
Haploidentical — 8 (18) —
AML indicates acute myelogenous leukemia; ALL, acute lymphoblastic leu-
kemia; MDS, myelodysplastic syndrome; MTX, methotrexate.
Table 3
Total Number and Time to Colon Biopsy for the UCBT and Control Groups
Characteristic UCBT (n ¼ 45),
n (%)
Control (n ¼ 45),
n (%)
P Value
Number of biopsies 75 53 —
Number of patients with
2 biopsies
23 (51) 6 (13) <.001
Number of patients with
3 biopsies
6 (13) 2 (4) .14
Time to ﬁrst biopsy, d,
median (IQR)
97 (83-117) 93 (86-107) .41
Time to second biopsy, d,
median (IQR)
104 (85-146) 132 (107-265) .10
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The total number of endoscopic procedures was 75 in the
UCBT group and 53 in the control (Table 3). In the UCBTTable 2
Treatment at Time of Colon Biopsy for the UCBT and Control Groups
Treatment UCBT (n ¼ 45),
n (%)
Control (n ¼ 45),
n (%)
P Value
B&B 18 (40) 21 (46) .52
Cyclosporine 28 (62) 6 (13) <.0001
MMF 27 (60) 11 (24) .0006
Sirolimus 8 (17) 4 (8) .21
Tacrolimus 10 (22) 35 (77) <.0001
Steroids 18 (40) 21 (46) .52
Inﬂiximab 2 (4) 0 .15
Antiviral therapy
Acyclovir 12 (26) 25 (55) .003
Valacyclovir 17 (37) 7 (15) .003
Foscarnet 2 (4) 2 (4) .003
Gancyclovir 9 (20) 11 (24) .003
Valgancyclovir 5 (11) - .003
Antifungal therapy
Voriconazole 13 (29) 12 (27) .80
Posoconazole 3 (6) 2 (4) .80
Fluconazole 13 (29) 11 (24) .80
Fluoroquinolones 3 (6) 2 (4) .64
Metronidazole 3 (6) 5 (11) .29
Dapsone 14 (31) 13 (29) .81
TMP/SMX 26 (57) 28 (62) .66
B&B indicates beclomethasone and budenoside; TMP/SMX, trimethoprim/
sulfamethoxazole.group, 23 patients (51%) underwent 2 endoscopic pro-
cedures, compared with only 6 patients (13%) in the control
group (P< .001). Of the 23 UCBT recipients who underwent a
second colonoscopy, 6 (26%) underwent a third endoscopic
procedure, and only 1 (4%) underwent a third. Of the 6
control group patients who had a second colonoscopy, 2
(33%) patients underwent a third endoscopic procedure. The
median time to ﬁrst colonoscopy was 97 days (interquartile
range [IQR], 83 to 117 days) in the UCBT group and 93 days
(IQR, 86 to 107 days) in the control group. No differences
between cases and controls were seen with respect to the
time to a second endoscopic procedure and the time interval
between the ﬁrst and second procedures.
In the UCBT group, the primary indications for the ﬁrst
endoscopic procedure were watery diarrhea (n ¼ 10);
abdominal pain, nausea, and anorexia (n ¼ 34); and bloody
diarrhea (n ¼ 1). In the control group, 11 patients underwent
colon biopsy because of watery diarrhea, whereas in the
remaining patients the primary indications for biopsy were
abdominal pain, nausea, and anorexia.
Clinical characteristics of UCBT recipients with watery
diarrhea are shown in Table 4. The median time of onset was
96 days (IQR, 85 to 105 days) in the UCBT group and 10 days
(IQR, 7 to 15 days) in the control group. In 8 of the 10
UCBT recipients, diarrhea resolved after either starting or
increasing therapy with systemic corticosteroids. In the
remaining 2 UCBT recipients, diarrheawas attributed toMMF
toxicity in one and to CMV enteritis in the other. Neither
patient responded to initial treatment (stopping MMF and
starting foscarnet, respectively), but after a repeat colonos-
copy, and both patients were started on prednisone, with
clinical resolution of diarrhea. None of the 10 UCBT recipient
had recurrent diarrhea after therapy with glucocorticoids.
In the control group, the median time of onset of diarrhea
was 88 days (IQR, 84 to 105 days), and the median duration
was 10 days (IQR, 7 to 15 days). Eight of 11 patients with
diarrhea had clinical resolution after either starting or
increasing therapy with systemic corticosteroids. Two pa-
tients were diagnosed with C difﬁcile and responded to
therapy with metronidazole; 1 patient who was positive for
adenovirus did not have a clinical response to cidofovir but
subsequently responded after receiving treatment with an
antieTNF-a biological agent after being diagnosed with gut
GVHD.
Histopathological Findings
As shown in Table 5, the prevalence of architectural
distortion of colonic crypts was 65% in the UCBT group and
67% in the control group. In the majority of the colon bi-
opsy specimens analyzed, at least 1 apoptotic crypt cell
was identiﬁed; no apoptotic cells were identiﬁed in 16% of
Table 4
Clinical Characteristics of UCBT Recipients with Watery Diarrhea
Patient Symptoms Imaging Mucosal Appearance on Biopsy Treatment
Fever Watery Bowel
Movements
Weight
Loss*
Erythema Edema Ulceration Hemorrhagic Steroid Response Relapse
1 Yes Yes 0.4 Not done Yes Yes No No No No Yes
2 No Yes 3.2 Not done No Yes No No Yes Yes No
3 No Yes 1.5 Not done Yes No No No Yes Yes No
4 No Yes 0.4 Not done Yes Yes No No No No Yes
5 Yes Yes 0 Not done Yes Yes Yes No Yes Yes No
6 No Yes 3.8 Not done No Yes No No Yes Yes No
7 Yes Yes 1 Not done No Yes No No Yes Yes No
8 Yes Yes 0.7 Not done No Yes No No Yes Yes No
9 No Yes 0.3 Not done No No No No Yes Yes No
10 No Yes 2.7 Not done Yes Yes Yes Yes Yes Yes No
Total patients 4 (40) 10 (100) 9 (90) 0 5 (50) 8 (80) 2 (20) 1 (10) 8 (80) 8 (80) 2 (20)
* Median weight loss was 1 kg.
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Paneth cells were identiﬁed in two-thirds of the colon bi-
opsy specimens in cases, with no differences in frequency
between the 2 groups; Paneth cell metaplasia with col-
lections of Paneth cells beneath crypts was a rare occur-
rence. No biopsy specimens contained basal plasmacytosis.
The presence of increased eosinophils was more prevalent
in the UCBT group than in the controls (P ¼ .04). Granu-
lomas were present in only 1 patient in each group. His-
tological characteristics of acute GVHD in gastric and
duodenal mucosa were concurrently present in 77% and
67% of the UCBT and control groups, respectively. In the
colonic biopsies, grade II-III aGVHD was present in 37% and
31% of UCBT and control recipients, respectively. Overall,
the most common pattern observed was chronic active
colitis, present in 58% of the UCBT group and in 62% of the
control groupents. A pattern of active colitis was found in
23% of the UCBT group and 24% of the control group,
respectively.
Similar histological ﬁndings were found when the anal-
ysis was limited to the 21 patients (10 in the UCBT group and
11 in the control group) with watery diarrhea as the primary
indication for endoscopic biopsy (Table 5).Table 5
Histopathological Results
Variable All Patients Undergoing Endoscopic Procedures
UCBT (n ¼ 43),
n (%)
Control (n ¼ 42),
n (%)
Individual features
Granulomas 1 (2) 1 (2)
Paneth cells 28 (65) 28 (67)
Mucosal distortion 28 (65) 28 (67)
Apoptosis
None 7 (16) 11 (26)
1 16 (37) 9 (21)
2 20 (47) 21 (50)
Increased eosinophils 10 (23) 3 (7)
Histological grade
Upper gut acute GVHD 33 (77) 28 (67)
Lower gut acute GVHD
None 14 (33) 14 (33)
Grade I 13 (30) 14 (33)
Grade II-III 16 (37) 13 (31)
Composite pattern
Chronic active colitis 25 (58) 26 (62)
Chronic inactive colitis 6 (14) 4 (10)
Active colitis 10 (23) 10 (24)
Unclassiﬁed 2 (5) 2 (4)Microbiological Findings
We evaluated fecal microbiological samples performed
within 7 days from the date of biopsy. Five patients (10%) in
the UCBT group and 8 patients (17%) in the control group had
at least 1 positive fecal pathogen identiﬁed. In the UCBT
group, C difﬁcileeproducing B toxin was identiﬁed in 3 cases,
adenovirus in 1 case, and Candida glabrata in one. In the
control group, C difﬁcileeproducing B toxin was identiﬁed in
5 cases, norovirus in 2 cases, and C glabrata in 1 case.
DISCUSSION
The principal ﬁndings of this analysis of colon disease in
recipients of UCBT can be summarized as follows: (1) We
could not identify a histological entity called “cord blood
colitis” distinct from colitis after allogeneic non-CB he-
matopoietic cell transplantation, and (2) almost all of the
subjects with colitis that developed after day þ70 had acute
GVHD as the explanation, independent of the source of donor
hematopoietic cells. A recent report from a Tokyo group
demonstrated that chronic active colitis with granuloma and
Paneth cell metaplasia is not a speciﬁc feature of CCS,
because these ﬁndings are also present in GVHD and CMV
colitis [14]. These results suggest that CCS as a unique entity(n ¼ 85) Patients with Diarrhea (n ¼ 21)
P Value UCBT (n ¼ 10),
n (%)
Control (n ¼ 11),
n (%)
P Value
.99 0 1 (9) .99
.76 6 (60) 7 (64) .99
.76 6 (60) 8 (73) .66
.24 .15
1 (10) 6 (55)
4 (40) 3 (27)
5 (50) 2 (18)
.04 0 1 (9) .99
.48 9 (90) 8 (73) .99
.86 .86
4 (40) 6 (55)
3 (30) 3 (27)
3 (30) 2 (18)
.90 5 (50) 6 (55) .99
1 (10) 2 (18)
3 (30) 3 (27)
1 (10) 0
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microorganism unique to the northeast region of the United
States [15]. The discrepancy among centers with regard to
causes of colitis does not exclude the possibility that the
Boston cord colitis cohort had both GVHD and a second,
presumably infectious, colitis characterized by multicentric
granulomas.
The evidence implicating acute GVHD as the underlying
condition causing colitis in our patients, independent of
donor cell source, rests on several observations. The diag-
nosis of gastrointestinal GVHD is usually based on the pres-
ence of the following features: (1) typical signs and
symptoms in a patient at risk; (2) endoscopic ﬁndings of
mucosal edema and erythema, often associated with focal
erosions and ulcerations of mucosa; (3) cardinal histological
changes inmucosal biopsy specimens, namely apoptotic cells
along the abluminal surface of the basolateral portion of
colonic crypts; (4) absence of gut pathogens by centrifuga-
tion culture for viruses, microscopy of mucosal biopsy
specimens, and analysis of fecal specimens; and (5) response
to immunosuppressive therapy in most patients. Intestinal
imaging tests (computed tomography enterography, positron
emission tomographyecomputed tomography, magnetic
resonance enterography, microbubble ultrasound, and
luminal contrast radiographs) also show characteristic
changes in the presence of gut GVHD. In our analyses, the
clinical presentation of colon disease, its timing, and features
of mucosal histology were similar in cases and controls, and
there was nearly universal response to immunosuppressive
therapy with glucocorticoids.
Herrera et al. [8] reported that all Bostonpatientswith CCS
responded a 10- to 14-day course of therapy with metroni-
dazole alone or in combinationwith a ﬂuoroquinolone. None
of our study patients with watery diarrhea was treated with
antibiotics, yet all responded to systemic corticosteroid
therapywithout experiencing recurrent episodes. In contrast,
45% of the Boston patients with CCS had recurrent diarrhea
after discontinuation of antibiotics, with subsequent resolu-
tion after restarting antibiotic therapy. There are several po-
tential explanations for the differing observations in CB
allograft recipients in Boston, Tokyo, and Seattle: (1) Antibi-
otics are treating an enteric organism that is the cause of
colitis in Boston; (2) antibiotics are modifying the clinical
presentation of acute GVHD via effects on the microﬂora and
its translocation through the mucosal barrier; (3) colitis can
be related to use of MMF, which causes gastrointestinal
mucosal injury thatmimics GVHD; and (4) cord colitismay be
a mélange of different entities.
According to Herrera et al. [8], the distinguishing histo-
logical characteristics of cord colitis included a paucity of
apoptotic crypt cells combined with features of chronicity,
such as Paneth cell metaplasia, crypt distortion, a pattern of
chronic active colitis, and, of singular importance, granuloma
formation. In our study, we did not ﬁnd histological evidence
of frequent or multicentric granulomas in either UCBT cases
or controls, or any association of UCBT with a particular
histological pattern or individual features. The frequency of
individual Paneth cells was equally distributed among the
UCBT case and control cohorts. Paneth cell metaplasia occurs
in inﬂammatory conditions including GVHD [9,14,16-18]. We
and others failed to identify Paneth cell metaplasia with
clustering beneath the crypts in our respective CB recipients
[14]. Findings such as chronic active colitis, neutrophilic
inﬂammation, and crypt distortion have been described in
GVHD [19].Not surprisingly, we found a strong association of colonic
GVHD with concurrent histological evidence GVHD of the
upper gut. Moreover, concomitant symptoms of presumed
upper gut GVHD (anorexia, nausea, vomiting) occurred in the
majority of the study patients with diarrhea, and vice versa.
This further supports the histopathological interpretation of
the ﬁndings in the colon as those of GVHD rather than with
an entity with distinct epidemiolgic, histological, and clinical
features [20]. Eosinophilia and eosinophilic crypt abscess
formation are known features of gut GVHD [21]. The greater
prevalence of mucosal eosinophils among a few UCBT re-
cipients reinforces the idea of an underlying GVHD process in
the gastrointestinal tract [20,21].
As part of the diagnostic process, we integrated the
clinical and pathological ﬁndings with information about
infection at the time of biopsy. In our cohort, we did not
identify any gut pathogens in the patients with diarrhea in
the UCBT group. Since the initial report of CCS [8], Bhatt et al.
[15] performed shotgun DNA sequencing on archival
formalin-ﬁxed, parafﬁn-embedded colon biopsy specimens
from 2 of the CCS cohort and identiﬁed a novel bacterial
species, Bradyrhizobium enterica. The investigators sug-
gested a possible infectious association of this organism
with CCS [15]. Furthermore, they cautioned that their ﬁnd-
ings from a single-institution cohort require conﬁrmation in
other institutional studies. Recently, a group from Austria
noticed, in a presumed case of CCS, overgrowth of Bacter-
oides fragilis, which was barely detectable after successful
therapy [22]. Unanswered are why Bradyrhizobium enterica
was not isolated in all Boston patients with CCS, and the
reason for its speciﬁc tropism in patients undergoing UCBT
and not allograft recipients whose donor cells were derived
from BM or PB.
In summary, our data offer no support for the existence of
a cord colitis syndrome at our center in 10 CB recipients with
diarrhea as the primary indication for biopsy and in an
additional 35 CB recipients with gastrointestinal symptoms.
We conﬁrmed that late-onset diarrhea is a relatively frequent
event after UCBT but is similar in frequency and clinical
characteristics to what occurred in recipients of transplants
from non-CB hematopoietic cell sources. We failed to iden-
tify any constellation of histological ﬁndings that are signif-
icantly speciﬁc to UCBT recipients compared with allograft
controls. In our UCBT cohort, the frequency of apoptotic
changes in the colonic mucosa and the rapid response to
corticosteroid therapy point to GVHD as the underlying cause
of gastrointestinal symptoms. The blinded review of the bi-
opsy specimens allowed us to perform a fair comparison
between UCBT recipients and controls with no inﬂuence of
symptoms or selection biases.
Our ﬁndings raise a concern about delaying immuno-
suppressive therapy for gastrointestinal GVHD in patients
with late-onset diarrhea after UCBT. The propensity of UCBT
recipients to develop late-occurring gut GVHD reinforces the
importance of rapid diagnosis followed by appropriate
treatment, with the proviso that a diagnosis of gastrointes-
tinal GVHD based on clinical, endoscopic, and histological
grounds does not preclude the concurrent presence of an
enteric pathogen. Future studies of mucosal histology and
microbiology will need to deﬁne the accuracy and predictive
value (positive and negative) of granulomas, Paneth cell
metaplasia, and Bradyrhizobium enterica in fecal specimens
in the diagnosis of CCS. Until these data are available, a
course of empiric antibiotics seems reasonable when the
cause of colitis is not obvious, as long as rapidly progressive
F. Milano et al. / Biol Blood Marrow Transplant 20 (2014) 1008e1013 1013mucosal necrosis caused by GVHD is not neglected as part of
the treatment plan.
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